Correction to “Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts”

Documenti analoghi

• Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
  di: Meirav Kedmi, et al.
  Pubblicazione: (2024)
• Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs
  di: Tze Wei Chan, et al.
  Pubblicazione: (2025)
• PET2‐Adapted Therapy in Patients With Advanced‐Stage Hodgkin Lymphoma Treated With Frontline ABVD: Searching for the Baby in the Bathwater
  di: Antonio Pinto, et al.
  Pubblicazione: (2024)
• Routine Monitoring of CAR‐T‐Cells Expansion and Persistence in Patients With Aggressive Large B‐Cell Lymphoma by Flow Cytometry: A Single‐Center Experience
  di: Alexandra Zduniak, et al.
  Pubblicazione: (2025)
• Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
  di: Giacomo Loseto, et al.
  Pubblicazione: (2025)